Definitive Contract 00266199804D266985339

The National Institute of Allergy and Infectious Diseases issued a delivery order to Advanced Bioscience Laboratories, Inc. on September 26, 2014, with a ceiling value of $1,260,134.13 for preclinical development support and toxicity testing for the CH505 T/F GP120 protein. The order is a cost-plus-fixed-fee engagement with place of performance in Rockville, MD. Performance extends through August 31, 2017. The work encompasses toxicity testing and preclinical development services in support of...

This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL) for R&D and medical support services related to AIDS research. The contract has a ceiling value of $2,857,610.47 and a period of performance through August 29, 2024. This award is not associated with a set-aside program. ABL, a foreign-owned, for-profit...

This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Advanced Bioscience Laboratories, Inc. (ABL), a contract research and manufacturing organization specializing in gene therapies, vaccines, and immunotherapies. The $712,676.73 cost-plus-fixed-fee delivery order contract requires ABL to conduct a study to characterize the pharmacokinetic profile of a candidate...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a delivery order valued at $3.78M to Advanced Bioscience Laboratories, Inc. (ABL) on August 31, 2024, for feasibility studies on developing a liposome/lipid nanoparticle (LNP) displaying an HIV envelope trimer protein and incorporating messenger RNA (mRNA). The contract, which extends through August 27, 2028, operates under a cost-plus-fixed-fee pricing structure with no set-aside designation. Work will be performed at...

This is a definitive federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Southern Research Institute, a corporate entity tax-exempt non-profit organization. The contract, valued at $2,900,275.00, is for AIDS research (basic) work and does not have a set-aside designation. Southern Research Institute, doing business as Southern Research, has a history of providing drug discovery, development, and...

This is a definitive, cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services' National Institutes of Health (NIH), to Diadexus, Inc., a for-profit manufacturer, for AIDS research activities. The contract has a potential value of $80,286,861.00 and a completion date of April 3, 2007. The contract was awarded on September 30, 2003 and does not have a set-aside designation. The place of...

This is a delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods. The $1,529,440.80 cost-plus-fixed-fee contract provides statistical support for HIV non-vaccine biomedical prevention product development under NIAID's "Comprehensive Resources for HIV Microbicides and Biomedical Prevention"...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded Research Triangle Institute (RTI International) a $1.48 million delivery order on August 1, 2024, for HIV assay development and testing to identify targeted activator of cell kill molecules. The contract is structured as a cost-plus-fixed-fee arrangement with performance scheduled through September 14, 2026, and will be executed at RTI's Research Triangle Park, North Carolina facility. This delivery order is issued under...

<p>The National Institute of Allergy and Infectious Diseases issued a delivery order to Advanced Bioscience Laboratories, Inc. on September 25, 2014, with a ceiling value of $494,513.97, for preclinical development support including expression and production of HIV-1 envelope protein.</p> <p>Place of performance is Rockville, MD. The delivery order is priced on a cost-plus-fixed-fee basis with an ultimate completion date of September 25, 2017. No set-aside was used.</p>

This federal contract award was issued by the Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases to Advanced Bioscience Laboratories, Inc. (ABL). The $510,898.00 contract is for the development and testing of messaging to drive adoption and use of HIV prevention products among young, urban and per-urban South African women. The contract is a delivery order under the HIV Microbicides and Biomedical Prevention 2016-2021...